|
|
|
| Effects of Aspirin, Clopidogrel combined with Tirofiban on platelet activity and prognosis in acute coronary syndrome patients with PCI |
| SONG Wei LIN Zujin CAI Haipeng |
| Department of Internal Medicine-Cardiovascular, Taizhou Central Hospital, Zhejiang Province, Taizhou 318000, China |
|
|
|
Abstract Objective To analyze the effect of Aspirin and Clopidogrel combined with Tirofiban on prognosis and platelet activity in acute coronary syndrome patients with PCI. Methods From January 2016 to August 2017, in Taizhou Central Hospital, 80 patients with acute coronary syndrome treated with PCI were selected, according to random envelope method, they were divided into the observation group and the control group, with 40 patients in each group. The control group was treated with Aspirin and Clopidogrel, and the observation group was treated with Aspirin and Clopidogrel combined with Tironon. The level of hs-CRP, sCD40L and PAR in the blood of the patients were detected, the incidence of adverse reaction was analyzed. Results After treatment, the level of hs-CRP and sCD40L in the observation group was significantly lower than those in the control group, the differences were statistically significant (P < 0.05). On 12 h given drugs, 6 h after finished given drugs, the level of PAR in the observation group was lower than that in the control group, the differences were statistically significant (P < 0.05), the level of PAR in two groups before treatment, On 12 h given drugs, 6 h after finished given drugs were compared, the differences were statistically significant (P < 0.05), the level of PAR before treatment was the highest, and the level of PAR on 12 h given drugs was the lowest. The bleeding and thrombocytopenia complications in the observation group and the control group were comapred, the differences were not statistically significant (P > 0.05). Conclusion The use of Aspirin, Clopidogrel and Tirofiban in the treatment of PCI patients with acute coronary syndrome can effectively inhibit platelet activity and improve the quality of the patients' prognosis, it has high clinical value.
|
|
|
|
|
|
[1] Bobadilla RV. Acute coronary syndrome：focus on antiplatelet therapy [J]. Critical Care Nurse，2016，36（1）：15.
[2] 席少枝，尹彤，陈韵岱.急性冠状动脉综合征患者经皮冠状动脉介入治疗术后抗栓与出血风险评估[J].中国介入心脏病学杂志，2017，26（11）：639-645.
[3] Esteve-Pastor MA，Hernández-Romero D，Valdés M，et al. New approaches to the role of thrombin in acute coronary syndromes：quo vadis bivalirudin，a direct thrombin inhibitor? [J]. Molecules，2016，21（3）：284.
[4] Choudhury T，West NE，El-Omar M. ST elevation myocardial infarction [J]. Clin Med，2016，16（3）：277.
[5] Wang N，Vendrov KC，Simmons BP，et al. Urinary 11-dehydro-thromboxane B2 Levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease [J]. Prostaglandins Other Lipid Mediat，2017， 134（7）：24-31.
[6] 中华医学会.心血管疾病防治指南和共识2013[M].北京：人民卫生出版社，2013.
[7] Varιm C，Varιm P，Acar BA，et al. Usefulness of the platelet-to-lymphocyte ratio in predicting the severity of carotid artery stenosis in patients undergoing carotid angiography [J]. Kaohsiung J Med Sci，2016，32（2）：86.
[8] Deloughery TG. Thrombocytopenia in Critical Care Patients [J]. J Crit Care，2016，17（6）：267-282.
[9] 胡菁，周全魁，谢艳丽.替罗非班联合氯吡格雷对老年急性冠脉综合征患者血小板功能、炎症因子及心功能的影响[J].中国老年学杂志，2017，37（5）：1136-1138.
[10] Ariotti S，Leeuwen MV，Brugaletta S，et al. Effects of ticagrelor，prasugrel，or clopidogrel at steady state on endothelial function [J]. J Am Coll Cardiol.，2018，71（11）：1289-1291.
[11] Qu JY，Xi J，Zhang YH，et al. Association of the MicroRNA-146a SNP rs2910164 with ischemic stroke incidence and prognosis in a Chinese population [J]. Int J Mol Sci，2016，17（5）：660.
[12] Sawardekar SB，Patel TC，Dinesh U. Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation： Anin vitrostudy [J]. Indian J Pharmacol，2016，48（1）：26-31.
[13] 赵发兵，姚卫.血清sCD40L、sCD40含量与ACS患者病情进展、斑块性质改变的关系[J].海南医学院学报，2017， 23（3）：310-312.
[14] Ding L，Gu Z，Wang R，et al. Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles： A case report [J]. Medicine，2017，96（47）：e8920.
[15] Li KC，Yu SH，Zhuge BZ. PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease [J]. Medicine，2017，96（36）：e7566.
[16] Xu XS，Yan X，Puchalski T，et al. Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma [J]. Clin Pharmacol Ther，2017，101（6）：721-724.
[17] Lu M. Report：impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack [J]. Pak J Pharm Sci，2017，30（1）：217-221.
[18] Michniewicz E，Mlodawska E，Lopatowska P，et al. Patients with atrial fibrillation and coronary artery disease——double trouble [J]. Adv Med Sci，2017，63（1）：30.
[19] 陆胜，余再新，黄友良，等.不同剂量替罗非班联合替格瑞洛对NSTEMI患者短期心血管事件及血小板聚集率的影响[J].心脏杂志，2017，39（4）：427-430.
[20] Kochman J，Rymuza B，Huczek Z，et al. Incidence，predictors and impact of severe periprocedural bleeding according to varc-2 criteria on 1-year clinical outcomes in patients after transcatheter aortic valve implantation [J]. Inter Heart J，2016，57（1）：35.
[21] Zi-Liang W，Xiao-Dong L，Tian-Xiao L，et al. Intravenous administration of tirofiban versus loading dose of oral clopidogrel for preventing thromboembolism in stent-assisted coiling of intracranial aneurysms [J]. Inter J Stroke，2017，12（5）：553-559.
[22] Yoon CH，Lee HW，Kim YS，et al. Preliminary study of tirofiban infusion in coil embolization of ruptured intracranial aneurysms [J]. Neurosurgery，2017，82（1）：76.
[23] Jia H，Lu C，Sun P. Intracoronary administration of tirofiban during percutaneous coronary intervention facilitates patients with acute coronary syndrome [J]. Oncotarget，2017， 8（63）：107 303-107 311. |
|
|
|
